- Home
- BDRX
as 06-06-2025 4:00pm EST
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
| Founded: | 2000 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.01 - $41.50 | Next Earning Date: | 04-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Biodexa Pharmaceuticals plc News
BDRX Breaking Stock News: Dive into BDRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
TipRanks
7 days ago
Biodexa Pharmaceuticals sees cash runway into 1Q26
GlobeNewswire
8 days ago
Shareholder Update
GlobeNewswire
16 days ago
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting
GlobeNewswire
16 days ago
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M
GlobeNewswire
a month ago
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
GlobeNewswire
a month ago
Result of General Meeting
GlobeNewswire
2 months ago
Notice of General Meeting
Compare BDRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDRX Biodexa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.